Statement of Ownership (sc 13g)
September 28 2021 - 04:31PM
Edgar (US Regulatory)
Securities and Exchange Commission
Washington, D.C. 20549
Schedule 13G
(Rule 13d-102)
Information to be Included in Statements Filed
Pursuant
to § 240.13d-1(b), (c) and (d) and
Amendments Thereto Filed
Pursuant to § 240.13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )*
Ginkgo Bioworks Holdings, Inc.
(Name of Issuer)
Class A Common Stock
(Title of Class of Securities)
37611X100
(CUSIP Number)
September 16, 2021
(Date of Event Which Requires Filing of this
Statement)
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
* |
The remainder of this cover page shall be filled out
for a reporting person’s initial filing on this form with respect
to the subject class of securities, and for any subsequent
amendment containing information which would alter the disclosures
provided in a prior cover page.
|
The information required in the remainder of this cover page shall
not be deemed to be “filed” for the purpose of Section 18 of
the Securities Exchange Act of 1934 (“Act”) or otherwise subject to
the liabilities of that section of the Act but shall be subject to
all other provisions of the Act (however, see the Notes).
|
|
|
|
|
CUSIP No.
37611X100 |
|
Schedule 13G |
|
Page 1 of 5 |
|
|
|
|
|
|
|
1 |
|
Names of Reporting Persons
Thomas Knight
|
2 |
|
Check the Appropriate Box if a Member of a Group
(a) ☐ (b) ☐
|
3 |
|
SEC Use Only
|
4 |
|
Citizenship or Place of Organization
United States
|
|
|
|
|
|
|
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
|
|
5 |
|
Sole Voting Power
9,219,119
|
|
6 |
|
Shared Voting Power
65,963,933
|
|
7 |
|
Sole Dispositive Power
9,219,119
|
|
8 |
|
Shared Dispositive Power
65,963,933
|
|
|
|
|
|
|
|
9 |
|
Aggregate Amount Beneficially Owned by Each Reporting
Person
75,183,052
|
10 |
|
Check if the Aggregate Amount in Row (9) Excludes
Certain Shares
Not Applicable
|
11 |
|
Percent of Class Represented by Amount in Row 9
5.6%
|
12 |
|
Type of Reporting Person
IN
|
|
|
|
|
|
CUSIP No.
37611X100 |
|
Schedule 13G |
|
Page 2 of 5 |
ITEM 1. |
(a) Name of Issuer:
|
Ginkgo Bioworks Holdings, Inc. (the “Issuer”).
|
(b) |
Address of Issuer’s Principal Executive
Offices:
|
27 Drydock Avenue, 8th Floor, Boston, MA 02210.
ITEM 2. |
(a) Name of Person Filing:
|
Thomas Knight (the “Reporting Person”).
|
(b) |
Address or Principal Business Office:
|
The business address of the Reporting Person is c/o Ginkgo Bioworks
Holdings, Inc., 27 Drydock Avenue, 8th Floor, Boston, MA 02210.
|
(c) |
Citizenship of each Reporting Person is:
|
The Reporting Person is a citizen of the United States.
|
(d) |
Title of Class of Securities:
|
Class A common stock, par value $0.0001 per share
(“Class A Common Stock”).
37611X100
Not applicable.
(a-c)
The ownership information presented below represents beneficial
ownership of Class A Common Stock of the Issuer as of
September 16, 2021, based upon 1,330,072,374 shares of
Class A Common Stock outstanding.
|
• |
|
Amount beneficially owned: 75,183,052
|
|
• |
|
Number of shares the Reporting Person has:
|
|
|
|
|
|
CUSIP No.
37611X100 |
|
Schedule 13G |
|
Page 3 of 5 |
|
• |
|
Sole power to vote or direct the vote: 9,219,119
|
|
• |
|
Shared power to vote: 65,963,933
|
|
• |
|
Sole power to dispose or direct the disposition of: 9,219,119
|
|
• |
|
Shared power to dispose or direct the disposition of:
65,963,933
|
The share amount reported herein consists of (i) 9,219,119 shares
of Class B common stock, $0.0001 per share, of the Issuer (the
“Class B Common Stock”) held of record by the Reporting
Person; (ii) 6,995,255 shares of Class A Common Stock held of
record by the Knight Family Trust dated August 20, 2019; (iii)
49,976,145 shares of Class A Common Stock held of record by
the Thomas F. Knight, Jr., Trustee of The Thomas F. Knight Jr.
Grantor Retained Annuity Trust or his/her successor in trust; and
(iv) 8,992,533 shares of Class A Common Stock held of record
by the Thomas F. Knight Jr. Grantor Retained Annuity Trust
(2) dated December 16, 2020. The Reporting Person serves
as co-trustee for the
Thomas F. Knight, Jr., Trustee of The Thomas F. Knight Jr. Grantor
Retained Annuity Trust or his/her successor in trust and the Thomas
F. Knight Jr. Grantor Retained Annuity Trust (2) dated
December 16, 2020, and the Reporting Person’s spouse serves as
co-trustee for the Knight
Family Trust dated August 20, 2019. As such, the Reporting
Person may be deemed to share beneficial ownership over the shares
held of record by each of the trusts.
The shares of Class B Common Stock may be redeemed by the
holder at any time for shares of Class A Common Stock on a
one-to-one basis. 8,055,129 of
the reported shares constitute earn-out shares subject to forfeiture,
which vest in four substantially equal installments if the
Class A Common Stock achieves a price per share for any period
of 20 trading days out of 30 consecutive trading days prior to
September 16, 2026 that equals or exceeds the following
thresholds: $12.50, $15.00, $17.50 and $20.00.
ITEM 5. Ownership of Five Percent or Less of a
Class.
Not applicable.
ITEM 6. Ownership of More Than Five Percent on Behalf of
Another Person.
Not applicable.
ITEM 7. Identification and Classification of the Subsidiary
which Acquired the Security Being Reported on by the Parent Holding
Company.
Not applicable.
ITEM 8. Identification and Classification of Members of the
Group.
Not applicable.
|
|
|
|
|
CUSIP No.
37611X100 |
|
Schedule 13G |
|
Page 4 of 5 |
ITEM 9. Notice of Dissolution of Group.
Not applicable.
ITEM 10. Certification.
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect, other
than activities solely in connection with a nomination under
§240.14a-11.
|
|
|
|
|
CUSIP No.
37611X100 |
|
Schedule 13G |
|
Page 5 of 5 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement
is true, complete and correct.
Date: September 27, 2021
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Apr 2022 to May 2022
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From May 2021 to May 2022